Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disorders
worldwide. It is associated with clinical states such as obesity, insulin resistance, and type 2 …

Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions
(ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are …

Background & Aims Emerging data suggest that changes in intestinal permeability and
increased gut microbial translocation contribute to the inflammatory pathway involved in …

Abundant evidence has demonstrated that obesity is a state of low-grade chronic
inflammation that triggers the release of lipids, aberrant adipokines, pro-inflammatory …

Obesity and the metabolic syndrome are closely correlated with hepatic steatosis. Simple
hepatic steatosis in nonalcoholic fatty liver disease can progress to nonalcoholic …

Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized pathology with a
high prevalence and a possible evolution to its inflammatory counterpart (non-alcoholic …

Despite the high prevalence of nonalcoholic fatty liver disease (NAFLD), therapeutic options
and noninvasive markers of disease activity and severity remain limited. We investigated the …

BACKGROUND/AIMS: The farnesoid X receptor (FXR) is a member of the nuclear hormone
receptor superfamily, which plays an essential role in the regulation of enterohepatic …

Background Liver biopsy is considered the gold standard for assessing histologic lesions of
non-alcoholic fatty liver disease (NAFLD). The aim was to develop and validate a new …

Non-alcoholic fatty liver disease (NAFLD) has been on a global rise. While animal models
have rendered valuable insights to the pathogenesis of NAFLD, discrepancy with patient …